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The arachidonate inhibition of the adenylate-cyclase system of cultured pig thyroid cells was not mediated 
by cyclooxygenase, lipoxygenase or peroxidase metabolites. Indeed ETYA, an inhibitor of cyclooxygen- 
ase and lipoxygenase, and methimazole, an inhibitor of peroxidase and iodination were without effect on 
the arachidonate inhibition. Moreover the effect of arachidonate was amplified by a combination with 
ETYA. In 32P incorporation experiments we observed a modification of the labelling of individual phos- 
pholipids of cultured pig thyroid cells resulting in a decrease into phosphatidylinositol (PI) and an increase 
into phosphatidate (PA) of arachidonate and ETYA-treated cells. These results may be explained by an 
inhibition of CDP-diacylglycerol : inositol transferase and conversely a stimulation of PI specific phospho- 
lipase C yielding a decrease in PI and an increase in PA, which inhibits in turn adenylate cyclase activity 
possibly by Ca*+ translocation. 
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Phospholipid 
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1. INTRODUCTION 
In [1] we studied the effect of arachidonate on 
cultured pig thyroid cells metabolism: in the ade- 
nylate cyclase system, the inhibitory effect of 
arachidonate (0.1 mM) on the thyrotropin (TSH) 
stimulation decreased with ageing of the culture; 
with thyroid protein iodination, we obtained stim- 
ulation of iodination by arachidonate in l-day or 
4-day cultured control cells and a dramatic inhibi- 
tion by arachidonate of the iodination of 4-day 
TSH-treated cells. On phospholipid metabolism, 
the ‘chronic TSH phospholipid effect’ [2] of 4-day 
cultured cells was completely abolished by an 
‘acute’ arachidonate treatment. 32P Incorporation 
into phosphatidylinositol was dramatically inhib- 
ited whereas 32P incorporation into phosphatidyl- 
choline was almost unchanged. 
of the adenylate-cyclase sytem is not mediated by 
cycle-oxygenase, lipoxygenase, or peroxidase 
metabolites. The results are compatible with an in- 
hibition of the PA-PI cycle and an effect of the 
phosphatidate on the adenylate cyclase system as 
described in other tissues [ 11,121. 
2. MATERIALS AND METHODS 
2.1. Preparation, culture, washings of thyroid cells 
The preparation, the culture and washing of 
thyroid cells were as in [1,2]. The ‘chronic treat- 
ment’ was applied during the culture period of the 
cells. The ‘acute treatment’ took place during the 
incubation of the cells after the washings. 
2.2. Cyclic AMP assay 
In thyroid, the arachidonate liberated by the 
TSH action on specific PI phospholipases [3-61, 
which is a substrate for cycle-oxygenase and lip- 
oxygenase [3,7-91, modulates phospholipid me- 
tabolism [ 1] and the iodination process [ 1, lo]. 
These results show that arachidonate inhibition 
Aliquots (400 ~1, 0.1-0.3 mg protein) from 
washed thyroid cell suspension were preincubated 
for 15 min at 37°C in 500 ~1 Earle’s Hepes buffer 
(pH 7.2) containing arachidonate, ETYA or meth- 
imazole, then incubated for 5 min in 700 ~1 of the 
same buffer containing isobutylmethylxanthine 
(IBMX 10-3 M) and with or without TSH 
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(40 mu/ml). The incubation was terminated by 
addition of 78 ~1 10 N HC104. The cyclic AMP 
content was assayed by a radioimmunological 
method [131 as in [2]. 
2.3. Phospholipid assay 
The 3*P incorporation assay in total and individ- 
ual phospholipids was as in [2]. The PI(cpm/mg 
protein) :PC(cpm/mg protein) ratio was calculated 
as an index of the ‘phospholipid effect’. Phos- 
phorus was determined as in [ 141. 
2.4. Thyroid protein iodination (PB 1251) 
After washing, the cells were incubated for 
45 min at 37°C in Earle’s Hepes buffer (pH 7.2) in 
700 ~1 final vol. containing 1 &i Nat*51. At the 
end of the incubation, 1.3 ml Earle’s Hepes buffer 
containing KI (lo-4 M) and bovine serum al- 
bumin fraction V (5 mg/ml) then 2 ml cold 20% 
(w/v) trichloroacetic acid were added. After cen- 
trifugation (500 x g for 5 min) the pellet was resus- 
pended and washed with cold 10% trichloroacetic 
acid (2 times) then the pellet was counted as PB 
t*sI (protein-bound iodine). 
2.5. Other methods and chemicals 
Protein estimation was done as in [ 151 using 
bovine serum albumin fraction V in 0.1 M NaOH 
as a standard. Aliquots of cells were centrifuged 
and the pellets solubilized in 0.1 M NaOH. Bovine 
TSH 3.5 IU/mg (NIAMDD, bTSH I&) and ovine 
TSH 7.5 IU/mg (NIAMDD, oTSH 9) were a gift 
of the NIH (Bethesda MD). [3*P]Orthophosphate 
(10 mCilm1) and Nat*51 (2 mCi/ml) were pur- 
chased from the CEN Saclay, [14C]arachidonate 
(50 Ci/mol) from the Radiochemical Centre 
(Amersham). Trypsin was purchased from Gibco, 
new-born calf serum from Flow Labs (Irvine), 
minimum essential medium from Merieux (Lyon), 
arachidonic acid from Applied Science Labs and 
methimazole from Sigma. Indomethacin was a gift 
from Merck, Sharp and Dohme; eicosatetraynoic 
acid (ETYA) was a gift from Hoffman-La Roche. 
2.6. Statistical evaluations 
The statistical differences were calculated using 
Student’s t-test; mean values of triplicate deter- 
minations were expressed with standard errors of 
the mean (SEM). Experiments were reproduced 
2-3 times with very similar or identical results. 
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3. RESULTS 
The results obtained with ETYA (0.1 mM) on 
the cyclic AMP responsiveness to TSH of l-day to 
4-day cultured control cells and TSH (0.1 mu/ml) 
treated cells are shown in table 1. At day 1 the 
results were very similar either with control or with 
TSH-treated cells. We observed an inhibition of 
the cyclic AMP responsiveness toTSH with ETYA 
(0.1 mM). The inhibitory effect of arachidonate on 
the cyclic AMP responsiveness to TSH [l] was not 
decreased by the addition of ETYA but the two 
inhibitory effects were ‘synergic’. At day 4, we con- 
firmed the decrease of the cyclic AMP responsive- 
ness to TSH in control cultured cells [ 16- 181 and 
the set-up of the positive regulation of the adenyl- 
ate cyclase in TSH-treated cells. In the latter cells, 
ETYA (0.1 mM) slightly decreased the cyclic AMP 
responsiveness to TSH. Arachidonate at 0.1 mM 
did not decrease the cyclic AMP responsiveness to 
TSH but 0.25 mM arachidonate was effective [ 11. 
A combination of arachidonate (0.1 mM) and 
ETYA (0.1 mM) provoked an important decrease 
of the cyclic AMP content. These results excluded 
an action of arachidonate on the cyclic AMP re- 
sponsiveness to TSH via lipoxygenase or cyclo- 
oxygenase metabolites. Fig. 1 summarizes the re- 
sults obtained with ETYA on protein iodination. 
At day 4 we confirmed the decrease of the protein 
iodination on control cultured cells and the high 
increase of the protein iodination on TSH-treated 
cells. ETYA (0.1 mM) provoked an important de- 
crease of the protein iodination of TSH-treated 
cells. The very important negative effect we also 
obtained [l] with arachidonate (0.1 mM) was not 
suppressed by ETYA but elevated. The results also 
exclude an action of arachidonate on the protein 
iodination of the thyroid cultured cells by lipoxy- 
genase or cycle-oxygenase metabolites. 
In [IO] peroxidase metabolites of arachidonate 
were shown in rat thyroid. The conversion of 
arachidonate into those metabolites was stimulated 
by ETYA and decreased by the peroxidase inhibi- 
tor methimazole (MMI). The effect of 0.5 mM 
MM1 on the cyclic AMP responsiveness to TSH of 
l-day or 4-day cultured cells is shown in table 2. 
On l-day control-cultured cells MM1 did not mod- 
ify the TSH responsiveness of the cyclic AMP con- 
tent and the negative effect of arachidonate. The 
results were quite similar on l-day TSH-treated 
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Table 1 
Effect of ETYA on the cyclic AMP responsiveness to TSH of l-day or 4-day cultured control cells and 
TSH-treated cells 
One-day- One-day TSH- Four-day- Four-day TSH- 
cultured treated cells cultured treated cells 
1 Acute treatment control cells (0.1 mu/ml) control cells (0.1 mu/ml) 
TSH C2o:4 ETYA 
40 mu/ml 0.1 mM 0.1 mM (pmol cyclic AMP/mg protein + SEM) 
(1) - - - 152 1 182 1 172 1 162 2 
(2) + - - 134+3c 159+5c 45k2C 342+ 3c 
(3) - - 
(4) - -’ + 
lo? la 9+ lb 12+ la 192 Ia 
11*1a 10% lb 152 la 152 la 
(5) - + + 82 lb 7f lb 11+1a 7+ la 
(6) + - 
(7) + -’ + 
37k3d 52+2d 39+ le 328 f 13e 
55?2d 71+3d 36+2e 283+ gf 
(8) + + + 6+ Id 9+ Id 8+ ld 50+ 2d 
a Not statistically different from corresponding control d P < 0.00 1 vs assay no. 2 
b PcO.01 YS corresponding control e Not statistically different from assay no. 2 
c PC 0.001 vs corresponding control f P < 0.0 1 vs assay no. 2 
After washing, the cells were preincubated for 15 min at 37°C in Earle’s Hepes in presence of ETYA or 
arachidonate. Then the incubation was pursued for 5 min in presence of IBMX (lo-3 M) with or 
without TSH (40 mu/ml) 
P B? cpm/ 
ng protein 
IO6 
5.105 
T 
7 
* 
L L I I I I ; I 
Fig.1. Effect of ETYA on the protein iodination of I-day TSH-treated cells. After washing, the cells were incubated for 
45 min at 37°C in Earle’s Hepes in presence of effecters as in section 2.4. 
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Table 2 
Effect of methimazole on the cyclic AMP responsiveness to TSH of l-day- or 4-day-cultured control 
cells and TSH-treated cells 
i 
One-day- 
cultured 
control cells 
One-day TSH- Four-day ,Four-day TSH- 
treated cells cultured treated cells 
(0.1 mu/ml) control cells (0.1 mu/ml) 
TSH c20:4 MM1 
40 mu/ml 0.25 mM 0.5 mM (pmol cyclic AMP/mg protein f SEM) 
(1) - _ - 
(2) - _ + 
(3) - + 
(4) - + + 
(5) + _ _ 
(6) + _ + 
(7) + 
(8) + + + 
222 2 242 3 
242 2” 20+- 3a 
162 la 202 2” 
15+ 2a 16+ 2a 
246+ 17b 252+ lib 
226 + 8b,c 234k 8b,c 
38k 4e 40+ 3e 
292 3a,d 32k 3a,d 
302 4 
312 3a 
292 2” 
212 3a 
104+ 2b 
97 + 1occ 
282 3a,e 
262 2a.d 
232 2 
252 la 
312 3a 
302 2a 
685 +- 27b 
74 1 +- 4ob.c 
328 k 30e 
348 + 25s 
a Not statistically different from corresponding control 
b P<O.OOl vs corresponding control 
e Not statistically different from assay no. 8 
f P < 0.01 vs corresponding control 
c Not statistically different from assay no. 5 
d P<O.OOl vs assay no. 5 
g P-c 0.01 vs assay no. 5 
MM1 = methimazole 
Experimental methods as in table 1 
Table 3 
Effect of arachidonate 0.25 mM on the phospholipid metabolism of 4-day-cultured control cells and 4-day TSH-treated 
cells (32P incorporation in cpm/mg protein) 
Chronic treatment 4-day-cultured control cells 4-day TSH-treated cells (0.1 mu/ml) 
Acute treatment No addition Arachidonate 0.25 mM No addition Arachidonate 0.25 mM 
Phospholipid cpm/mg protein W cpm/mg protein % cpm/mg protein % cpm/mg protein 5% 
PLT 2150+40 _ 760560 - 3560+350 - 165Okl70 - 
PI 1140225 53 190220 25a 23402280 65.5 4104 90 24a 
PC 5102 5 24 185220 24 640+ 40 18 8OOk 80 49 
PS 130+ 10 6 100+ 10 13.5 140+ 15 4 8025 5 
PE 120+ 5 5.5 1 lo+ 10 14.5 2OOk 15 6 702 5 4.5 
PA 250? 10 12 1702 11 22.5a 26Ok 20 7.5 3OOk 10 18” 
PI/PC 2.23 1.02 3.65 0.51 
aP< 0.00 1 vs corresponding control 
After washing, the cells (0.1-0.3 mg protein) were incubated for 2 h at 37°C in Earle’s Hepes buffer (pH 7.2) in 
presence of (32Plorthophosphate (10 PCi) with or without arachidonate in 700 ~1 final vol. The incubation was termi- 
nated by addition of a chloroform-methanol mixture (2: 1, v/v). Phospholipids were extracted and analyzed as in [2] 
Abbreviations: PLT, total phospholipids; PI, phosphatidylinositol; PC, phosphatidylcholine; PS, phosphatidylserine; 
PE, phosphatidylethanolamine; PA, phosphatidic acid 
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Table 4 
Effect of ETYA on the phospholipid metabolism of 4-day-cultured control cells and 4-day TSH-treated cells 
([s*P]orthophosphate incorporation into total or individual phospholipids; cpm/mg protein) 
Chronic treatment 4-day-cultured control cells 4-day TSH-treated cells (0.1 mu/ml) 
Acute treatment No addition ETYA 0.1 mM No addition ETYA 0.1 mM 
Phospholipid cpm/mg protein 96 cpm/mg protein % cpm/mg protein % cpm/mg protein % 
PLT 2150+40 - 760230 - 35602350 - 380-+10 - 
PI 1140225 53 1502 10 22a 23402280 65.5 80+10 2la 
PC 5102 5 24 200+ 10 28.5 6402 40 18 100+ 10 25.5 
PS 130+ 10 6 80_+ 5 11 140* 15 4 602 5 16 
PE 1202 5 5.5 952 5 14 200~ 15 6 702 5 17.5 
PA 2502 5 12 lEO+lO 25a 26Ok 20 7.5 75+ 5 19.5a 
PI/PC 2.23 0.75 3.65 0.80 
aP< 0.001 vs corresponding control 
Experimental methods as in table 3 
cells. On 4-day control and TSH-treated cells, we 
confirmed the lack of response to MM1 at the 
negative control level by arachidonate of the cyclic 
AMP responsiveness toTSH. 
Here, the negative control by arachidonate of 
the cyclic AMP responsiveness toTSH also seemed 
to be ‘independent’ from the synthesis of perox- 
idase metabolites. 
We confirmed, under the same conditions (not 
shown) the inhibition by MM1 protein iodination. 
In [l] we described the arachidonate effect on 
the thyroid phospholipid metabolism. The most 
important effect was on 4-day TSH-treated cells 
and was characterized by an acute effect on the PI 
turnover that was decreased by 0.1 mM arachido- 
nate. The phosphatidate metabolism was un- 
changed (not shown). The effect of 0.1 mM arach- 
idonate on the cyclic AMP responsiveness to TSH 
of 4-day TSH-treated cells was very small. In the 
presence of 0.25 mM arachidonate we described 
an acute effect on the cyclic AMP responsiveness 
to TSH of 4-day TSH-treated cells. 
On phospholipid metabolism, 0.25 mM arach- 
idonate provoked very important modifications 
(table 3). The 32P incorporation into total phos- 
pholipids was decreased and there was a very dif- 
ferent pattern of the distribution between individ- 
ual phospholipids. The relative 76 of 32P acutely 
increased in phosphatidate and acutely decreased 
in PI of 4-day control and TSH-treated cells. 
The effect of ETYA on the phospholipid metab- 
olism is shown in table 4. ETYA (0.1 mM) which 
provoked a significant decrease of the cyclic AMP 
responsiveness to TSH of 4-day control and TSH- 
treated cells, modified the phospholipid pattern in 
the same way as 0.25 mM arachidonate. The 32P 
incorporation into total phospholipids decreased, 
the relative % of 32P acutely increased in phos- 
phatidate and acutely decreased in PI. 
The effect of phosphatidate on the cyclic AMP 
responsiveness toTSH of control and TSH-treated 
cells is shown in table 5. Phosphatidate decreased 
the stimulation by TSH of the cyclic AMP content. 
4. DISCUSSION 
After thyroid cultured cells in various physiolog- 
ical conditions have been challenged with 0.1 mM 
arachidonate or 0.1 mM ETYA, or both, the fol- 
lowing observations can be made: both fatty acids 
decreased the cyclic AMP accumulation and the 
protein iodination, ETYA being more efficient on 
a molar basis. As we reported [l] 4-day TSH-treat- 
ed cells are less sensitive to the arachidonate inhi- 
bition; it is also true of ETYA inhibition. When 
the two acids were administered together, the 
effect is more than additive but may be compared 
to that of 0.25 mM arachidonate [l]. Two main 
conclusions can be drawn from these results. 
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PAI 
(40 mu/ml) (pmol cyclic AMP/mg protein k SEM) 
(1) - 22*2 24+3 3024 23+ 2 
(2) - 1 PM 2122a 25+3a 28+6a 26+ 4a 
(3) - 10 /rM 20f 3a 22+ 5a 26%4a 20+ 2a 
(4) + 246 r 12b 2522 lib 104 + 2b 685 + 27b 
(5) + 1 PM 2022 5c 193-t 15e 80+5d 6OOk 18C 
(6) + lO/rM 178+ 9d 1522 1Od 59r6d 453 f 12d 
a Not statistically significant corresponding control d P~0.01 vs assay no. 4 
b PC 0.001 vs corresponding control e PC 0.05 vs assay no. 4 
f Not statistically significant vs assay no. 4 PA = phosphatidic acid 
Experimental methods as in table 1 
(1) Arachidonate does not need to be metabolized 
to inhibit the cyclic AMP accumulation and the 
protein iodination. Indeed ETYA is a potent 
inhibitor of the known enzymes metabolizing 
arachidonate in thyroid: cycle-oxygenase [lo] 
and lipoxygenase [9]. 
(2) ETYA, which does not inhibit the arachidonate 
effects, reinforces and reproduces them with 
better efficiency. 
Novel metabolic transformations of arachido- 
nate were reported in thyroid [lo]; the amount of 
the conversion was increased by ETYA and inhib- 
ited by MMI. Our result, showing a synergy be- 
tween arachidonate and ETYA, is compatible with 
the formation of the new metabolites. Since the 
conversion into the metabolites may be controlled 
by an iodinated compound [lo] we tested the effect 
of MM1 on the cyclic AMP accumulation in cells 
submitted to TSH and arachidonate action. At a 
concentration which completely prevents iodinat- 
ing processes, MM1 is devoid of effect. This result 
allows us to discard the intervention of those new 
metabolites as effecters of arachidonate at the 
cyclic AMP level. 
We have reported previously that 0.1 mM arach- 
idonate, which is not very efficient in decreasing 
the cyclic AMP accumulation in 4-day TSH- 
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treated cells, lowers the 32P incorporation into 
phospholipids, decreasing in particular PI labelling 
[ 11. Here, we have studied the incorporation of 32P 
into 4-day control and TSH-treated cultured cells, 
challenged with 0.25 mM arachidonate or 0.1 mM 
ETYA. This higher concentration of arachidonate 
was chosen, because it produces a decrease in the 
stimulated cyclic AMP accumulation even in 4-day 
TSH-treated cells (table 2). 
These results confirm our previous ones con- 
cerning the decreased general incorporation of 3* P 
into phospholipids, especially into PI. Moreover, 
they bring new information. While the phosphati- 
date labelling did not increase at 0.1 mM arachido- 
nate (not shown in [l]), it actually did at 0.25 mM. 
ETYA at 0.1 mM gives the same kind of results 
as 0.25 mM arachidonate, suggesting once more 
that the observed effect is not consecutive to a met- 
abolic transformation. 
These observations may be explained by the re- 
sults in [ 191 showing the inhibition by arachidonate 
and other unsaturated fatty acids of CDP-diacyl- 
glycerol:inositol transferase and conversely the 
stimulation of PI-specific phospholipase C from 
rat liver also described in rat brain [20]. 
In a 3*P incorporation study, the simultaneous 
stimulation of degradation and inhibition of syn- 
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thesis of PI (by arachidonate or ETYA) would pro- 
duce a decreased labelling of PI and an increased 
one of PA. This is actually what we observed in 
our experiments (tables 3,4). 
Phosphatidic acid at the PM level was reported 
to mimic the carbachol inhibition of PGEt-stimu- 
lated cyclic AMP accumulation in WI 38 fibro- 
blasts [ll]. As our system exhibits the carbachol 
inhibition at the adenylate cyclase level [21,22] we 
have tested the action of PA. Under the conditions 
we applied to thyroid cultured cells acutely stimu- 
lated by TSH, we observed a modest but signifi- 
cant inhibition of cyclic AMP accumulation. The 
weakness of the inhibition may be explained by 
the dual mode of action of TSH which simul- 
taneously stimulates adenylate cyclase, raising the 
cyclic AMP level and produces a phospholipid 
effect with a PA increase, which in turn decreases 
the cyclic AMP level. The actual level of cyclic 
AMP assayed under TSH stimulation would be the 
balanced result of 2 antagonistic effects, positive 
and negative ones. As acknowledged [23], the 
negative effecters of adenylate cyclase maximally 
produce - 60% inhibition. In our conditions a part 
of the inhibitory sites is occupied by endogenous 
PA due to the negative effect of TSH, the re- 
mainder only being available to exogenous PA. 
We can present the following hypothesis to ex- 
plain arachidonate and ETYA modes of action: 
Both fatty acids, without metabolic transforma- 
tion, inhibit CDP-diacylglycerol:inositol trans- 
ferase and stimulate phospholipase C activity, 
yielding a decrease in PI and an increase in PA, 
which inhibits in turn adenylate cyclase activity 
possibly by Ca2 + translocation [24]. 
A similar blockade of the PA-PI cycle was de- 
scribed 1251 in platelets. 
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